Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus DORYX MPC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus DORYX MPC.
ATRIDOX vs DORYX MPC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic